⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17604203 | 0.95 | HRH4 (0.36) | — | |
| SCHEMBL1786021 | 0.93 | KMO (0.37) | — | |
| SCHEMBL232190 | 0.91 | — | — | |
| SCHEMBL8130205 | 0.83 | — | — | |
| SCHEMBL3308039 | 0.83 | HRH4 (0.42) | — | |
| Hydrochloric Acid SCHEMBL9134652 | 0.81 | HRH4 (0.41) | — | |
| Hydrochloric Acid SCHEMBL949115 | 0.81 | HRH4 (0.41) | — | |
| SCHEMBL7672211 | 0.81 | ESR2 (0.35) | — | |
| SCHEMBL8017350 | 0.79 | HTR1D (0.38) | — | |
| SCHEMBL12147714 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888259-B1 | DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE | NOVARTIS AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| EP-2888259-B1 | DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE | NOVARTIS AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20170305903-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20170305903-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20170305903-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| US-9650377-B2 | Diazepinone derivatives | NOVARTIS AG (CH) | 2017-05-16 | — | — | US | disclosed |
| US-9650377-B2 | Diazepinone derivatives | NOVARTIS AG (CH) | 2017-05-16 | — | — | US | disclosed |
| US-9650377-B2 | Diazepinone derivatives | NOVARTIS AG (CH) | 2017-05-16 | — | — | US | disclosed |
| CN-104520298-B | For treating two azepines ketone derivatives of fragile X syndrome, parkinson disease or reflux disease | 诺华股份有限公司 | 2016-10-19 | — | — | CN | disclosed |
| US-20160159795-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20140357625-A1 | DIAZEPINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8853203-B2 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-10-07 | — | — | US | disclosed |
| US-8853203-B2 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-10-07 | — | — | US | disclosed |
| US-8853203-B2 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-10-07 | — | — | US | disclosed |
| US-20140057902-A1 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| WO-2014030128-A1 | DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE | NOVARTIS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| US-20140057902-A1 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-20140057902-A1 | Diazepinone derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| EP-0719258-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-03 | — | — | EP | disclosed |
| WO-1996002508-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |